EA200301057A1 - Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот - Google Patents

Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот

Info

Publication number
EA200301057A1
EA200301057A1 EA200301057A EA200301057A EA200301057A1 EA 200301057 A1 EA200301057 A1 EA 200301057A1 EA 200301057 A EA200301057 A EA 200301057A EA 200301057 A EA200301057 A EA 200301057A EA 200301057 A1 EA200301057 A1 EA 200301057A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
metabolism
compositions
regulation
connections
Prior art date
Application number
EA200301057A
Other languages
English (en)
Other versions
EA006556B1 (ru
Inventor
Даниелли Пиомелли
Фернандо Родригес Де Фонсека
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of EA200301057A1 publication Critical patent/EA200301057A1/ru
Publication of EA006556B1 publication Critical patent/EA006556B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Предлагаются способы, фармацевтические композиции для снижения веса, регулирования метаболизма липидов в организме и снижения потребления пищи у млекопитающих. Заявленные в изобретении соединения включают производные этаноламида жирных кислот, их гомологи и аналоги, ближайшим аналогом которых является эндогенный этаноламид жирных кислот, в частности олеилэтаноламид.
EA200301057A 2001-03-27 2002-03-27 Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот EA006556B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27954201P 2001-03-27 2001-03-27
US33628901P 2001-10-31 2001-10-31
PCT/US2002/009773 WO2002080860A2 (en) 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism

Publications (2)

Publication Number Publication Date
EA200301057A1 true EA200301057A1 (ru) 2004-04-29
EA006556B1 EA006556B1 (ru) 2006-02-24

Family

ID=26959730

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301057A EA006556B1 (ru) 2001-03-27 2002-03-27 Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот

Country Status (11)

Country Link
US (3) US6911474B2 (ru)
EP (1) EP1408945A4 (ru)
JP (1) JP2004526745A (ru)
KR (1) KR20030087657A (ru)
CN (1) CN1523982A (ru)
AU (1) AU2002338329B2 (ru)
CA (1) CA2442683A1 (ru)
EA (1) EA006556B1 (ru)
IL (1) IL158131A0 (ru)
MX (1) MXPA03008823A (ru)
WO (1) WO2002080860A2 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1523982A (zh) 2001-03-27 2004-08-25 ���������Ǵ�ѧ���»� 减少体脂和调节脂肪酸代谢的方法、化合物和组合物
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
US20050118232A1 (en) † 2002-02-12 2005-06-02 Elvira Pistolesi N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
WO2004034968A2 (en) * 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
WO2004045307A2 (en) * 2002-11-18 2004-06-03 Natural Asa Dietry supplements and foods product comprising oleylethanolamide
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
CA2542547A1 (en) * 2003-10-16 2005-05-26 Daniele Piomelli Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
EP1570752B1 (en) * 2004-03-06 2008-07-02 Cognis IP Management GmbH Verwendung von ungesättigten Fettsäuren zur Verringerung des Appetits oder der Essensaufnahme
JP2006061086A (ja) * 2004-08-27 2006-03-09 Morishita Jintan Kk 脂肪代謝改善効果を有する被験試料のスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2007006319A2 (en) * 2005-07-14 2007-01-18 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
CA2681668C (en) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
MEP27308A (en) 2006-04-11 2010-06-10 Arena Pharm Inc Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US20090208513A1 (en) * 2007-09-07 2009-08-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Diagnostic And Therapeutic Uses Of Augmenter Of Liver Regeneration In Inflammatory Conditions
ES2291147B1 (es) * 2007-10-15 2008-11-01 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Derivados pirazolicos de amidas de acidos grasos como activadores especificos de receptores ppar-alfa, procedimiento de preparacion y utilizacion.
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
WO2009142713A1 (en) * 2008-05-19 2009-11-26 Nestec S.A. Methods for reducing lipid absorption by an animal
BR112012024214A2 (pt) * 2010-03-24 2019-09-24 Nestec Sa método para melhorar a palatabilidade de composições comestíveis.
CA2800301C (en) 2010-07-02 2018-03-27 Helix Biomedix, Inc. N-acyl amino acid derivatives for treating skin conditions such as cellulite
ES2579990T3 (es) 2011-01-19 2016-08-18 Terakine Therapeutics, Inc. Métodos y composiciones para tratar el síndrome metabólico
MX2013013098A (es) * 2011-05-10 2013-12-16 Nestec Sa Metodos y composiciones para fomentar el crecimiento de la masa corporal magra.
CN103619169A (zh) * 2011-05-10 2014-03-05 雀巢产品技术援助有限公司 用于在减肥期间保持瘦体重的方法和组合物
US8426471B1 (en) * 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN102579414A (zh) * 2012-01-29 2012-07-18 厦门大学 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途
WO2013160492A1 (es) * 2012-04-24 2013-10-31 Fundación Instituto Mediterráneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Imabis) Terapia combinada para el tratamiento de enfermedades metabólicas
US9221747B2 (en) 2012-04-25 2015-12-29 Iowa State University Research Foundation, Inc. Method of making fatty acid N-acylalkanolamines
CN102675141A (zh) * 2012-05-04 2012-09-19 庄信修 N-(2-羟基乙基)芥酰胺及其制备与用途
CN104602536A (zh) 2012-09-07 2015-05-06 雀巢产品技术援助有限公司 油酰乙醇胺组合物
CN102824338A (zh) * 2012-09-18 2012-12-19 厦门大学 s-油酰丙醇胺在制备降血脂、防治非酒精性脂肪肝药物中的用途
US8778981B2 (en) 2012-11-21 2014-07-15 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
CN103113253A (zh) * 2013-01-28 2013-05-22 国家海洋局第三海洋研究所 一种不饱和脂肪酸醇胺衍生物及其制备方法与应用
ES2498521B1 (es) * 2013-02-20 2015-08-18 Fundación Pública Andaluza Para La Investigación De Málaga En Biomedicina Y Salud (Fimabis) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
NO2753788T3 (ru) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
SG10201807034XA (en) 2017-09-05 2019-04-29 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505569D0 (sv) * 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
US5506224A (en) * 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
US5679667A (en) * 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
US5602164A (en) * 1992-04-28 1997-02-11 Senyorina Ltd. Anti-obesity drugs
US5554646A (en) * 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
IT1274783B (it) * 1994-12-15 1997-07-24 Antonio Picarelli Preparato per il trattamento dell'obesita'
WO1996029405A2 (en) * 1995-03-20 1996-09-26 Ligand Pharmaceuticals Incorporated MODULATORS OF ob GENE AND SCREENING METHODS THEREFOR
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
EP0904079B1 (en) 1996-02-02 2004-03-24 Merck & Co., Inc. Antidiabetic agents
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5803916A (en) 1996-03-19 1998-09-08 Vital-Tech Ltd. Body and joints massage device
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
AU776414B2 (en) * 1998-05-29 2004-09-09 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US6359010B1 (en) * 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
CN1438900A (zh) 2000-05-23 2003-08-27 加利福尼亚大学董事会 一种治疗咳嗽的新方法
CN1523982A (zh) 2001-03-27 2004-08-25 ���������Ǵ�ѧ���»� 减少体脂和调节脂肪酸代谢的方法、化合物和组合物
US7048941B2 (en) 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
JP5093967B2 (ja) * 2001-04-06 2012-12-12 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 睡眠時の自律的安定性に関するカンナビノイドの機能的役割
WO2003011220A2 (en) * 2001-07-31 2003-02-13 The Scripps Research Institute Animal model for fatty acid amide-related neurobehaviors
JP2005516986A (ja) 2002-02-08 2005-06-09 ブリストル−マイヤーズ　スクイブ　カンパニー （オキシム）カルバモイル脂肪酸アミド加水分解酵素インヒビター
WO2004045307A2 (en) 2002-11-18 2004-06-03 Natural Asa Dietry supplements and foods product comprising oleylethanolamide

Also Published As

Publication number Publication date
US7423066B2 (en) 2008-09-09
EA006556B1 (ru) 2006-02-24
WO2002080860A2 (en) 2002-10-17
US20090005447A1 (en) 2009-01-01
KR20030087657A (ko) 2003-11-14
AU2002338329B2 (en) 2006-09-07
AU2002338329C1 (en) 2002-10-21
CN1523982A (zh) 2004-08-25
IL158131A0 (en) 2004-03-28
JP2004526745A (ja) 2004-09-02
CA2442683A1 (en) 2002-10-17
EP1408945A2 (en) 2004-04-21
US20050187254A1 (en) 2005-08-25
EP1408945A4 (en) 2005-07-06
MXPA03008823A (es) 2004-08-12
US20030018081A1 (en) 2003-01-23
US6911474B2 (en) 2005-06-28
WO2002080860A3 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
EA200301057A1 (ru) Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот
WO2005046580A3 (en) Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
Draganidis et al. Inflammaging and skeletal muscle: can protein intake make a difference?
Lenzi et al. Lipoperoxidation damage of spermatozoa polyunsaturated fatty acids (PUFA): scavenger mechanisms and possible scavenger therapies
MY169519A (en) Nutritional compositions
BR0313957A (pt) Creme culinário e método de preparação do mesmo
MA28215A1 (fr) Formes galeniques de l'oxycodone à libération contrôlée pour administration orale une fois par jour
MXPA04009758A (es) Metodo y composicion dietetica para mejorar la digestibilidad de lipidos.
BR0008059A (pt) Composições de valdecoxib
CO5550402A2 (es) Composicion para disminuir el colesterol en la sangre
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
BRPI0515316A (pt) compostos de imidazoquinolina
BR0014377A (pt) Composição compreendendo proteina de caseìna e proteìna de soro
CY1108033T1 (el) Βελτιωμενη παιδιατρικη συνθεση και μεθοδοι για την παροχη τροφης και τη βελτιωση της ανεκτικοτητος
WO2003007888A3 (en) Fat accumulation-modulating compounds
WO2011078677A3 (en) Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
BR0211107A (pt) Formulações entéricas
WO2003099338A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2004034968A3 (en) Combination therapy for controlling appetites
EP1466621A4 (en) COMPOSITIONS FOR ENHANCING LIPID METABOLISM
TW200719908A (en) Dermatologic use of milk proteins
PH12021550331A1 (en) Acylated calcitonin mimetics
CO2021014835A2 (es) Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso
JP2005518353A5 (ru)
BRPI0309421A8 (pt) Método de preparar um gênero alimentício e composição para tratar ou prevenir hipercolesterolemia

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ MD RU